Memphasys (ASX:MEM) completed a clinical trial of its advanced sperm selection technology, Felix System, for assisted reproductive technology procedures, according to a Tuesday Australian bourse filing.
It achieved the last patient visit in the trial, with all required patient visits, including pregnancy outcomes completed, the filing said.
Data lock is anticipated in around two weeks, following a final data clean-up, management, and source verification phase.
It will use the trial data as part of its ongoing CE Mark submission to advanced commercialization activities in Europe. Regulatory approvals in Australia and India are expected to follow soon after.
The firm's shares rose past 14% on market close on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.